ACHV

Achieve is a pre-revenue, single-product clinical-stage biotech whose entire value rests on one asset: cytisinicline, a smoking-cessation candidate not yet FDA-approved. There is no product revenue (the XBRL revenue tag reads $0.00), so this is not a company you can value on fundamentals — it is a probability-weighted bet on a binary regulatory outcome. The FY2025 net loss widened to -$54.6M (from -$39.8M in FY2024, a -37.2% deterioration), driven by G&A nearly doubling to $31.9M on $12.3M of pre-approval commercial-launch preparation and R&D of $23.0M that includes raw cytisinicline inventory expensed before any approval exists. Operating cash flow was -$49.5M. Losses have compounded every year (-$33.2M→-$42.4M→-$29.8M→-$39.8M→-$54.6M) into a -$260M accumulated deficit.

The balance sheet is the disqualifier. Cash of $20.9M against a ~$49.5M annual operating burn is well under one year of runway, and management states plainly it 'will need to raise additional capital' to advance programs and service existing debt. Diluted share count already jumped 53.5% YoY to 53.2M — that dilution is not a risk, it is the observed funding mechanism, and the same mechanism will be used again. Buying here means buying ahead of a near-certain capital raise at an unknown (likely lower) price. Equity is a thin $21.5M and ROE is a meaningless -254% because the company is consuming its own capital.